Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical study of TAA06 injection in the treatment of advanced solid tumor

ABSTRACT: Interventions: Experimental group:TAA06 Cells for Infusion Primary outcome(s): Safety Study Design: Single arm

DISEASE(S): Malignant Melanoma, Lung Or Colorectal Cancer

PROVIDER: 35675 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Autologous multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma: results of a Phase I, three-arm, nonrandomized clinical trial (TACTOPS)

Project description:T-cell therapy has thus far proven ineffective for treating pancreatic ductal adenocarcinoma (PDAC), in part due to heterogeneous expression of tumor-associated antigens (TAAs). In a Phase I/II trial, autologous ex vivo expanded T-cells targeting five TAAs - PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1 - were prepared and administered (1x107 cells/m2/infusion) monthly to subjects with advanced PDAC responding (Arm A, n=13) or refractory to (Arm B, n=12) first-line chemotherapy, or to those with potentially resectable disease (Arm C, n=12). Primary endpoints were safety and feasibility of delivering 6 infusions; additional endpoints were clinical and immunologic response. Of 56 subjects procured, 37 were infused (median 3 doses), with only one treatment-related serious adverse event reported. Disease control rates in Arms A and B were 84.6% (95% CI: 54.6%-98.1%) and 25% (95% CI: 5.5%-57.2%), respectively; in Arm C, 2/9 resected subjects remain disease-free at 55 and 66 months. The infused cells persisted for up to 12 months post-infusion, and elevated levels of effector, tumor-directed T cells were detected both during dosing (p=0.027) and follow-up in “responders” (objective response in Arms A/B, no relapse in Arm C) compared to “non-responders” (progression in Arms A/B, relapse in Arm C).

2025-09-12 | GSE307914 | GEO

Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment.

Project description: Not available

| S-EPMC7716638 | biostudies-literature

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.

Project description: Not available

| S-EPMC9746060 | biostudies-literature

Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors.

Project description: Not available

| S-EPMC12161328 | biostudies-literature

Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors.

Project description: Not available

| S-EPMC7210722 | biostudies-literature

Clinical study on the safety and effectiveness of CAR-T cells in the treatment of advanced colorectal cancer

Project description:Interventions: experimental group:CART cells Study Design: Single arm

| 36200 | ecrin-mdr-crc

Phase I exploratory clinical study of CD276-targeted chimeric antigen receptor T cells for the treatment of solid tumors

Project description:Interventions: experimental group:CD276-targeted chimeric antigen receptor T cells Primary outcome(s): SAE rate Study Design: Single arm

| 2703905 | ecrin-mdr-crc

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.

Project description: Not available

| S-EPMC10178837 | biostudies-literature

A Clinical Trial of TAA06 Injection in Advanced Solid Tumors

Project description:B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn’t express on normal tissues. Therefore, B7-H3 is an ideal target for chimeric antigen receptor (CAR) T cells therapy. TAA06 injection is a CAR T injection targeting B7-H3. This is a phase I clinical study with the primary objective of evaluating the safety and tolerability of TAA06 injection in subjects with TAA06-positive advanced solid tumors. The secondary objectives are as follows: to evaluate the distribution, proliferation and persistence of B7-H3-targeted CAR T cells after injection of TAA06 in subjects; to preliminarily evaluate the efficacy of TAA06 injection in subjects with TAA06-positive advanced solid tumor.

| 2400863 | ecrin-mdr-crc

Hepatic arterial infusion chemotherapy (HAIC) combined with regorafenib and PD-1 inhibitors in the treatment of liver metastases of colorectal cancer after failure of second-line chemotherapy: a single-arm prospective, open-label phase II clinical trial

Project description:Interventions: Experimental group:Hepatic arterial infusion chemotherapy;Experimental group:Regorafenib;Experimental group:Intravenous infusion PD-1 inhibitors Primary outcome(s): Objective Response Rate (ORR) Study Design: Single arm

| 41970 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data